The online broker Avanza Bank's savers bought the most in Evolution, Novo Nordisk and Apotea in December, as well as in Investor, a returning favorite.

Evolution has lost over 10 percent this month on an investigation launched in the UK, and overall the stock is down 30 percent this year. But "savers believe in a turnaround and are buying," Avanza economist Philip Scholtzé said in a commentary.

Savers also picked up Novo Nordisk after the fall of over 20 percent in connection with the presentation of worse-than-expected phase 3 results for the company's weight loss drug. "Share savers are trying to dip into the stock, which is down nine percent since the beginning of the year," says Scholtzé.

Online pharmacy Apotea made its debut on the stock exchange in December, and there has been a lot of interest in the share. "The allocation that Avanza's customers received contributes to the share being one of the most bought, but the share is net bought even after the listing," says Scholtzé.

The most sold stocks were Tesla and Nvidia, both of which have performed very strongly this year.

BuyingSells
EvolutionTesla
Novo NordiskNvidia
Investor BAvanza
ApoteaH&M
NordeaSwedbank
VolvoSEB
MicroStrategyFortnox
NibeEricsson
SSAB BBetsson
HexagonCamurus